Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

The potential of LAG-3 targeting therapy to treat a number of ailments, particularly cancer, autoimmune diseases, and inflammatory diseases, has attracted a lot of attention to the global market.

LAG-3 is a popular target, and following after is a clutch of drugs in mid-stage development, including Immutep's soluble LAG-3 protein eftilagimod alpha, Novartis/Immutep's leramilimab, Incyte's ...

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Immutep Limited’s IMMP share price has dipped by 12.04%, which has investors questioning if this is right time to buy.